The Investors Most Likely to Sell Their Uber Stakes
Uber's valuation is reportedly down. That's according to Softbank's offer to buy shares of the ride-sharing company at a 30 percent discount. Axios' Dan Primack breaks down what this pending deal could mean for Uber.
The Japanese firm is leading a group that will purchase billions of dollars worth of shares from employees and investors at a $48 billion valuation, and invest about $1 billion in Uber at the previous valuation of $68 billion. Primack says most of this investment will go to early shareholders. The "unofficial" reason for the investment at the old valuation is that is the price Saudi Arabia's public investment fund bought in about a year ago.
Potential sellers, such as early investors and employees, have 20 business days to give Softbank an answer during the tender process. Primack called Softbank's price at a 30 percent discount an "opening bid," and doesn't see any way this deal is accomplished at this starting price. Ultimately, Uber CEO Dara Khosrowshahi needs this deal to get done because it's tied to governance changes, says Primack. It will give Khosrowshahi and the board more control, and former Uber CEO Travis Kalanick less control.
Joe Spector, founder of Dutch and Hims & Hers co-founder, joins us to discuss how telehealth is transforming pet care—and what’s next for modern vet medicine.
Exclusive: Behr’s Andy Lopez reveals how ChatHUE, a bold collaboration with Google, is using AI to transform how we explore, choose, and connect with color.
Brian Vendig, President & CIO of MJP Wealth Advisors, joins to break down Q2 bank earnings and what they signal for markets, investors, and the economy ahead.
Are Gen Z and Millennials done with alcohol? Bacardi's Tony Latham breaks down trends, new preferences, and insights from the 2025 Cocktail Trends Report.
Comscore’s Paul Dergarabedian breaks down the battle of summer blockbusters, from Superman to Jurassic World and Fantastic Four and what it means for studios.
VENU CEO JW Roth breaks ground on a 20,000-seat, state-of-the-art amphitheater in Texas—part of a $300M public-private expansion to redefine live music.
Despite healthcare spending cuts, medtech stocks like Edwards Life Sciences, Stryker, and Boston Scientific are rising, especially those serving older pati
